An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa; Usher Syndrome Type 2 Intervention: Drug: RNA antisense oligonucleotide for intravitreal injection Sponsor: ProQR Therapeutics Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials